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Death receptors (DRs) of the TNFR superfamily
contribute to antiviral immunity by promoting
apoptosis and regulating immune homeostasis
during infection, and viral inhibition of DR signaling
can alter immune defenses. Here we identify the
human cytomegalovirus (HCMV) UL141 glycoprotein
as necessary and sufficient to restrict TRAIL DR
function. Despite showing no primary sequence
homology to TNF family cytokines, UL141 binds the
ectodomains of both human TRAIL DRs with affini-
ties comparable to the natural ligand TRAIL. UL141
binding promotes intracellular retention of the DRs,
thus protecting virus infected cells from TRAIL and
TRAIL-dependent NK cell-mediated killing. The iden-
tification of UL141 as a herpesvirus modulator of the
TRAIL DRs strongly implicates this pathway as
a regulator of host defense to HCMV and highlights
UL141 as a pleiotropic inhibitor of NK cell effector
function.
INTRODUCTION
Tumor necrosis factor (TNF) family cytokines are crucial in
providing protection against virus infections through their
regulation of cell death and survival (Benedict, 2003). TNF family
cytokines mediate direct antiviral activity in infected cells
but also function to maintain immune homeostasis by limiting
tissue damage, largely by inducing apoptosis in effector
cells after infection is controlled. In turn, viruses encode324 Cell Host & Microbe 13, 324–335, March 13, 2013 ª2013 Elseviemechanisms to promote cell survival, facilitating successful
replication and transmission. The large DNA herpesviruses all
establish lifelong infection, and consequently they employ
many strategies to modulate cellular apoptotic signaling path-
ways. These range from restricting ligand-receptor interactions
to blocking caspase activation and activating prosurvival path-
ways (Loewendorf and Benedict, 2010; Mocarski et al., 2012;
Rahman and McFadden, 2006), ultimately impacting the dura-
tion of infection and the magnitude of downstream immune
responses.
Human cytomegalovirus (HCMV, human herpesvirus 5), the
prototype member of the Betaherpesvirinae, exhibits a ubiqui-
tous distribution worldwide and seroprevalence varies with
socioeconomic status, age, and geography. While infection is
commonly asymptomatic in healthy individuals, HCMV can
cause severe morbidity and mortality in both the immunocom-
promised and naive; vaccine development is a high priority
(Schleiss, 2007). Moreover, persistent/latent infection is associ-
ated with cancer and multiple autoinflammatory disorders
(Dziurzynski et al., 2012) (Baryawno et al., 2011; Cobbs et al.,
2002; So¨derberg-Naucle´r, 2006; Streblow et al., 2008), as well
as earlier all-cause mortality (Simanek et al., 2011). HCMV has
become a paradigm for immune modulation, and its study is
proving particularly insightful in characterizing the key mecha-
nisms responsible for regulating human NK cell function.
HCMV strategically restricts cell-surface expression of key
immune-activating proteins, including TNFR1-, MHC-I-, and
natural killer (NK)-cell-activating ligands (Loewendorf and
Benedict, 2010; Loureiro and Ploegh, 2006; Wilkinson et al.,
2008). UL141 is a type I transmembrane glycoprotein encoded
within the the right hand end of the UL (UL/b0) region of the
HCMV genome that was lost from the commonly-used labora-
tory strains AD169 and Towne during in vitro passager Inc.
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UL141 Targets TRAIL Death Receptors(Cha et al., 1996). UL141 is recognized to have potent NK cell
evasion function that acts by suppressing cell-surface expres-
sion of CD155, the ligand for the NK-cell-activating receptors
DNAM1 and CD96 (Tactile) (Prod’homme et al., 2010; Tomasec
et al., 2005; Xu and Jin, 2010). Moreover, UL141 has also
recently been shown to be instrumental in targeting the alterna-
tive DNAM1-activating ligand, CD112 (Prod’homme et al., 2010).
In humans, TNF-related apoptosis-inducing ligand (TRAIL/
TNFSF10) binds the death receptors (DRs) TRAIL-R1 (DR4)
and TRAIL-R2 (DR5). TRAIL also binds additional receptors
that do not encode death domains, including TRAIL-R3,
TRAIL-R4 and the secreted osteoprotegerin (OPG) receptor;
although sometimes referred to as ‘‘decoy receptors,’’ their roles
in regulating TRAIL signaling are poorly understood (Ashkenazi
and Dixit, 1999; Emery et al., 1998). Clustering of the TRAIL
DRs through interaction with their cognate ligand results in their
oligomerization, inducing formation of the death-inducing
signaling complex (DISC) consisting primarily of FADD and pro-
caspase-8 or procaspace-10 and, ultimately, caspase activation
and cellular apoptosis (Bodmer et al., 2000). NK cells produce
significant levels of TRAIL when activated by interferons (Sato
et al., 2001; Takeda et al., 2001), utilizing it as an effector mole-
cule to kill tumor cells (Feng et al., 2010; Hallett et al., 2008;
Smyth et al., 2001). In addition to its established antitumor
properties, TRAIL signaling plays a multifaceted role in antiviral
immunity, directly targeting infected cells through proapoptotic
mechanismswhile commensurately regulating immune effectors
(Cummins and Badley, 2009). Notably, infection of fibroblasts
with HCMV laboratory strain AD169 induces TRAIL-DR expres-
sion and sensitizes them to TRAIL killing (Sedger et al., 1999),
and HCMV can also induce TRAIL expression in infected
dendritic cells (DCs) (Raftery et al., 2001).
HCMV has acquired multiple strategies to counter the TNFR
superfamily, including inhibiting the expression and/or signaling
by the TNFR-1 and Fas DRs (Baillie et al., 2003; Jarvis et al.,
2006; McCormick et al., 2003; Skaletskaya et al., 2001b).
Paradoxically, HCMV also actively promotes upregulation of
TNFR-1 via the latency-associated UL138 protein (Le et al.,
2011; Montag et al., 2011). Moreover, UL144 is an ortholog of
HVEM (TNFRSF14) that binds the coinhibitory receptor BTLA
and potently inhibits T cell activation (Benedict et al., 1999;
Cheung et al., 2005). Here we show that UL141 binds multiple
TRAIL DRs through ectodomain interactions, suppressing their
cell-surface expression and protecting cells from TRAIL and
NK-cell-mediated killing, identifying it as a herpesvirus protein
that directly target TRAIL receptors. We propose the TRAIL
DR-UL141 interaction represents a countermeasure HCMV
has evolved in response to host immune pressure, and further
highlights the UL138-144 gene cluster as focused upon targeting
the TNFR superfamily.
RESULTS
Low-Passage HCMV Strains Inhibit Cell-Surface
Expression of the TRAIL Death Receptors
HCMV is known to inhibit signaling by DRs belonging to the
TNFR superfamily (e.g., TNFR-1 and Fas) (Baillie et al., 2003;
Jarvis et al., 2006; McCormick et al., 2003; Skaletskaya et al.,
2001b). However, HCMV isolates that have been passagedCell Hoextensively in cultured fibroblasts (e.g., the AD169 strain) can
differentially alter TNFR expression due to the loss of specific
immune modulatory proteins (Le et al., 2011; Montag et al.,
2011). Consequently, to address whether infection with HCMV
would target the TRAIL DRs, we analyzed fibroblasts infected
with distinct viral strains for their cell-surface expression. The
high-passage laboratory strain AD169 was used for infection
(variant ATCC), as well as the FIX strain of HCMV (originally
VR1814), which has been subjected to limited in vitro passage
and whose genome is available as an infectious clone in a bacte-
rial artificial chromosome (BAC) (Hahn et al., 2002; Murphy et al.,
2003). In contrast to AD169, FIX induced dramatic down-
regulation of both TRAIL DRs from the cell surface (Figure 1A).
The function was ascribed to a de novo FIX-encoded gene
product, as inhibition of DR expression was ablated by UV
irradiation of input virus (data not shown). Low-passage HCMV
strains therefore encode a function that downregulates cell-
surface expression of TRAIL-R1 and TRAIL-R2 that has been
lost from the laboratory strain AD169.
UL141 Is Implicated in the Inhibition of TRAIL-R2
Expression
In addition to other defects, strain AD169 has suffered a sponta-
neous 15 kb deletion from the UL/b0 region during passage
in vitro (Cha et al., 1996). Consequently, we utilized a HCMV
mutant generated in the FIX-BAC deleted in the majority of the
UL/b0 sequence (FIXDUL/b0 [Hahn et al., 2004]) to test for the
ability to restrict TRAIL DR expression. The UL/b0 region contains
R21 genes that are dispensable for viral replication in fibroblasts
(Gatherer et al., 2011). FIXDUL/b0 could not restrict cell-surface
expression of either TRAIL DR, indicating that an HCMV gene
contained within this region was required for their inhibition
(Figure 1A). Notably, cell-surface expression of TRAIL-R1 was
significantly increased after FIXDUL/b0 infection, and this was
consistent with enhanced messenger RNA (mRNA) expression
levels seen for this DR in HCMV infected fibroblasts (Figure S1A
available online).
Screening through theUL/b0 regionwith a panel of pre-existing
FIX BAC deletion mutants (Hahn et al., 2004) ruled out UL128,
UL129, UL130, UL131a, UL132, UL148a-d, C-orf23, C-orf25,
and C-orf26 in regulating the TRAIL DRs (data not shown). A
FIXD139-141 mutant was then constructed, and, when tested,
this mutant was incapable of inhibiting TRAIL DR expression,
with TRAIL-R1 being commensurately upregulated on the
cell surface similar to that seen with FIXDUL/b0 (Figure 1B).
Construction of a FIXDUL141 mutant then revealed that FIX
lacking an intact UL141 open reading frame (ORF) was incapable
of downregulating cell-surface expression of the TRAIL DR
(Figure 1B). Taken together, these results show that UL141 is
required to restrict cell-surface expression of TRAIL-R1 and
TRAIL-R2 in HCMV-infected cells.
A high level of sequence variation is present in HCMV clinical
isolates and cultured strains, although it is not evenly distributed
throughout the genome, and this variability has been shown to
impact immune evasion functions (Prod’homme et al., 2012).
To further examine and confirm the role of UL141 in regulating
TRAIL-R1 and TRAIL-R2 expression, we also specifically deleted
the gene from HCMV strain Merlin using BAC technology. The
Merlin BAC is currently accepted to be the most ‘‘geneticallyst & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc. 325
Figure 1. HCMV Restriction of TRAIL DR
Cell-Surface Expression Requires UL141
Neonatal human dermal fibroblasts (NHDFs) were
infected with the AD169 or FIX strains of HCMV or
various deletion mutants at a multiplicity of infec-
tion (MOI) of 2, and cell-surface levels of TRAIL-
R1 and TRAIL-R2 were analyzed 72 hr later by flow
cytometry. Black histograms, mock infected; gray
histograms, HCMV infected; shaded histograms,
isotype control staining of HCMV-infected cells.
Similar results were seen in four to six experi-
ments, and isotype control staining for mock-
infected cells was either similar to or slightly
lower than that displayed for binding to infected
cells (%23 MFI differences). See also Figure S1.
Cell Host & Microbe
UL141 Targets TRAIL Death Receptorsintact’’ cloned HCMV genome in the field, and as the FIX BAC
was deleted for the IRS-US6 locus during its construction, the
use of Merlin also provided additional confidence in results
obtained with FIX. Consistent with previous findings, UL141
was required for downregulation of CD155 by strain Merlin but
not for inhibition of MHC-I (Figure 2A). Whereas deletion of
UL141 from the FIX strain resulted in restoration of TRAIL-R2
level to those seen in uninfected cells (Figure 1B), in the Merlin
strain restoration was never complete, albeit expression levels
returned to >90% seen in mock-infected cells. This modest,
but reproducible, difference between DUL141 mutants of FIX
and Merlin suggest potential UL141-independent regulation of
the TRAIL DRs by HCMV may exist, and this is currently being
explored.
Expression Kinetics of UL141
Suppression of TRAIL-R2 cell-surface expression by HCMV
could be detected as early as 24 hr after infection, yet it became
more marked as the infection progressed through 48 and 72 hr
(Figure S1D). In strain FIX, UL141 is encoded by a single abun-
dant transcript initiated 213 bases upstream of the start codon
and extending to 39 bases downstream of the stop codon
(Figure S1B), compatible with recent transcriptional mapping
data for UL141 in strain Merlin (Gatherer et al., 2011). Consistent
with the kinetics of TRAIL-R2 downregulation, strain FIX UL141326 Cell Host & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc.was found expressed as an early-late
gene product (Figure S1E), increasing in
abundance dramatically throughout the
viral replication cycle (Figure S1C).
Fate of TRAIL-R2 in HCMV-Infected
Cells
We have previously shown that UL141
restricts the cell-surface expression of
CD155 and CD112, two NK-cell-acti-
vating ligands belonging to the nectin/
nectin-like family of proteins. Notably,
the mechanisms by which UL141 modu-
lates these two host cell proteins are
quite distinct. UL141 sequesters CD155
in the endoplasmic reticulum (ER) of
HCMV-infected cells (Tomasec et al.,
2005) yet promotes the proteasome-dependent degradation of CD112 (Prod’homme et al., 2010).
To gain insight into whatmechanism(s) of actionmight be utilized
by UL141 to target TRAIL-R2, we analyzed strain Merlin-infected
fibroblasts by western blot. Notably, fibroblasts infected with
Merlin showed demonstrably higher total cellular levels of
TRAIL-R2 when compared to uninfected cells or cells infected
with MerDUL141 (Figure 2B). A similar pattern of restricted
cell-surface expression, but enhanced total cellular expression,
of TRAIL-R2 was also observed in epithelial cells infected with
HCMV. In total, these data indicate that while UL141 functions
to inhibit cell-surface expression of TRAIL-R2 in HCMV-infected
cells, it appears to promote the accumulation of this DR in an
intracellular compartment.
UL141 Is Sufficient to Restrict TRAIL Death Receptor
Cell-Surface Expression
Studies with HCMV deletion mutants demonstrated that UL141
was required to provide efficient downregulation of the TRAIL
DRs at the cell surface. UL141 alone is sufficient to restrict
CD155 cell-surface expression (Tomasec et al., 2005), but addi-
tional HCMV-encoded functions are needed to target CD112
(Prod’homme et al., 2010). We therefore sought to determine
whether UL141 was able to target TRAIL DRs when expressed
in isolation. A UL141 expression plasmid was transfected into
both primary fibroblasts and 293T cells, and significant
Figure 2. TRAIL-R2 Expression in HCMV-Infected Cells
Human foreskin fibroblasts (HFFs) were infected (72 hr, MOI = 20) with
HCMV Merlin (Mer) or MerlinDUL141 (MerD141) and analyzed for TRAIL-R2
expression by (A) flow cytometry and (B) Western blot. IgG(–), isotype control
antibody staining. Results are representative of six to ten performed experi-
ments. See also Figure S2.
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proving that UL141 alone is sufficient to suppress TRAIL DR
expression (Figures 3A and 3B). Inhibition of TRAIL DRs was
also observed when a UL141-GFP fusion protein was stably
transfected into 293T cells, commensurate with enhanced accu-
mulation of intracellular TRAIL-R2, as seen in HCMV-infected
cells (data not shown). Additionally, an adenovirus vector encod-
ing UL141 also restricted TRAIL DR levels on the cell surface and
promoted its intracellular accumulation in both fibroblasts and
epithelial cells (Figures 3C, 3D, and S2). Together, these exper-
iments demonstrated that UL141 inhibits cell-surface expression
and promotes intracellular accumulation of the TRAIL DRwithout
the assistance of any additional HCMV-encoded function.
UL141 Interacts Directly with the Human TRAIL Death
Receptors
UL141 is a type I transmembrane glycoprotein with a short
C-terminal cytoplasmic domain, and structural algorithms
predict that it contains an immunoglobulin-like fold in its ectodo-
main (Tomasec et al., 2005). To determine whether UL141
targets the TRAIL DRs by directly binding to them, we expressed
and purified the UL141 ectodomain (UL141ecto) as well as
a fusion protein of the ectodomain with the Fc region of human
IgG1 (UL141:Fc). The binding assay demonstrated an interaction
between UL141:Fc and both TRAIL-R1:Fc and TRAIL-R2:Fc
(Figure S3A). While UL141:Fc binds to the surface of human
fibroblasts and 293T cells (data not shown), this result was not
informative as CD155 is also expressed at high levels on most
human cells. In contrast, UL141:Fc was incapable of binding toCell Homouse NIH 3T3 fibroblasts (which express mTRAIL-R2), but
transfection of hTRAIL-R2 into NIH 3T3 cells promoted strong
binding of UL141:Fc (Figure S3B), formally showing that UL141
can interact with cell-surface-expressed hTRAIL-R2. Consistent
with this result, binding between mouse TRAIL-R2:Fc and
UL141:Fc was not observed in an ELISA-based assay (data
not shown). Taken together, these data prove that UL141 binds
directly to both human TRAIL DRs.
In order to determine the binding kinetics/affinity of UL141 for
the TRAIL DRs, we conducted surface plasmon resonance anal-
ysis of UL141ecto binding to TRAIL-R1 and TRAIL-R2:Fc proteins
(Figure 4). UL141 was found to bind to TRAIL-R2 with a KD of
6nM, an affinity very close to that of TRAIL (2 nM [Truneh et al.,
2000]). In contrast, UL141 bound to TRAIL-R1 with a dramatically
lower affinity (KD = 2.3 mM), with differences in both the associa-
tion and dissociation kinetics being observed. The UL141 binding
kinetics to TRAIL-R1 revealed only a 2-fold slower association
rate (kon = 6.0 3 10
3 M1 s1), while dissociation was almost
200 times faster (koff = 1.4 3 10
2 s1), when compared to
UL141 binding to TRAIL-R2-Fc (kon = 1.2 3 10
4 M1 s1,
koff = 7.2 3 10
5 s1, Figure 4). Taken together, these results
confirm direct binding of UL141 to both human TRAIL DRs, but
with significantly lower affinity for TRAIL-R1, largely mimicking
how TRAIL binds its two cognate DRs (Truneh et al., 2000).
The fact that UL141 interacts directly with the TRAIL DRs is
interesting, as it shows no primary sequence or predicted struc-
tural homology to any TNF family ligands (Bodmer et al., 2002).
This raised the possibility that UL141 might interact with addi-
tional members of the TNFR superfamily. To test this, we used
UL141:Fc protein to stain 293T cells transfected with all the
known TNFRs (Figure S3C) (Bossen et al., 2006). In this assay
format, where positive controls were included for all receptor-
ligand interactions, strong binding of UL141:Fc (5 mg/ml) was
only detected to 293T cells transfected with TRAIL-R2. Notably,
binding of UL141:Fc under these conditions was not detected to
TRAIL-R1, most likely due to the relatively low binding affinity for
this DR compared to TRAIL-R2, as seen in SPR analyses.
Consequently, these data indicate that TRAIL-R2 appears to
be the only member of the TNFR superfamily that is a specific,
high-affinity target for UL141.
Intracellular Retention of TRAIL-R2 in the Presence
of UL141
Expression of TRAIL DRs is largely localized to intracellular
membrane compartments in lung and melanoma-derived cell
lines, with a minority of the total protein present on the plasma
membrane at steady state (Leithner et al., 2009; Zhang et al.,
2000). Virtually nothing is known regarding the mechanisms
that regulate the trafficking of TRAIL DRs through various cellular
compartments, although ER stress has been shown to upregu-
late TRAIL-R2 cell surface levels and sensitize them to TRAIL-
induced killing (Chen et al., 2007). To examine whether UL141
alters the subcellular localization of TRAIL-R2, we transduced
fibroblasts with adenoviral recombinants (RAds) encoding
UL141 and TRAIL-R2 constructs fused to C-terminal GFP or
RFP tags and lacking an intact death domain (averting apoptosis
mediated by overexpression of full-length TRAIL-R2) (e.g., RAd-
TRAILR2.GFP) (Figure 5). For comparison, cells were also trans-
duced with RAd-CD155.RFP or RAd-MICA.GFP. TRAILR2.GFPst & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc. 327
Figure 3. UL141 Is Sufficient to Inhibit Cell-
Surface Expression of TRAIL DR
(A) NHDF cells or (B) 293T cells cotransfected with
UL141 and a GFP expressing plasmid were
analyzed for cell-surface expression of the indi-
cated proteins by flow cytometry 48 hr later. Black
histogram, GFP(–) cells; gray histogram, GFP(+)
cells; gray shaded histogram, isotype control
binding to entire cell population. Human fibro-
blasts (HF-CAR) were infected (48 hr, MOI = 3) with
RAd-CTRL or RAd-UL141 and analyzed for TRAIL-
R2 expression by (C) flow cytometry and (D)
Western blot. Similar results were obtained in
three to five experiments.
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UL141 Targets TRAIL Death Receptorsand TRAILR2.RFP were expressed throughout a variety of
intracellular membrane compartments, on the cell surface, and
colocalized with endosomal markers (Figures 5A and 5K and
data not shown). In contrast, when this DR and UL141 were
coexpressed, TRAIL-R2 was restricted in large part to the ER,
(Figures 5F, 5P and S4A). UL141 also localizes primarily to the
ER, and not to the trans medial Golgi complex, in the absence
of coexpressed TRAIL-R2 or CD155 (Figure S4B). This pattern
of intracellular compartmentalization was similar to that
observed in cells transduced with RAd-CD155.RFP and UL141
(Figures 5G and 5H). The interaction between TRAIL-R2 and
UL141 was specific, as UL141 did not alter trafficking/localiza-
tion of MICA.GFP (Figures 5P and 5Q), which is known to be
downregulated from the cell surface through the action of
HCMV UL142 (Ashiru et al., 2009; Chalupny et al., 2006). Impor-
tantly, similar localization of TRAIL-R2 to the ERwas seen in cells
infected with wild-type Merlin but not MerDUL141 (Figure S4C).
Taken together, these data support biochemical analyses
showing that UL141 redirects and/or restricts TRAIL DR expres-
sion to an intracellular membrane compartment(s), mainly the
endoplasmic reticulum. Interestingly, this differs from the mech-
anism used by adenovirus E3 region proteins, which target
TRAIL DRs for lysosomal degradation (Benedict et al., 2001).
UL141 Functions Nonredundantly to Restrict
TRAIL-Mediated Killing
We sought to investigate whether the intracellular sequestration
of TRAIL-R2 by UL141 desensitized cells to TRAIL-mediated328 Cell Host & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc.apoptosis. To test this, we treated human
fibroblasts transduced with UL141 with
soluble TRAIL (Figure 6A). UL141-ex-
pressing cells showed dramatically
reduced activation of caspase-3/cas-
pase-7, proving that UL141 can desensi-
tize cells to apoptotic signaling mediated
by the TRAIL DR. This effect was
specific, as the sensitivity of UL141-ex-
pressing cells to TNF-mediated apoptotic
signaling was not overtly altered
(Figure 6A).
Next, the effect that UL141 restriction
of TRAIL DR cell-surface expression had
on altering the sensitivity of HCMV in-
fected cells to TRAIL killing was analyzed(Figure 6B). Fibroblasts infected with FIX were completely pro-
tected from TRAIL-mediated killing. In contrast, FIXDUL141-in-
fected cells were significantly more sensitive to TRAIL-induced
apoptosis, which was notable, as other potentially redundant
mechanisms targeting DR signaling are still operable in this
mutant virus (e.g., UL36-mediated inhibition of caspase-8 acti-
vation [Skaletskaya et al., 2001a]). To further explore this issue,
we analyzed the sensitivity of cells infected with HCMV strain
AD169 to TRAIL killing, as this strain encodes a nonfunctional
UL36 (Skaletskaya et al., 2001a) in addition to lacking UL141.
AD169-infected fibroblasts were even more sensitive to TRAIL
killing than those infected with FIXDUL141, consistent with
a model in which both UL36 and UL141 are likely to contribute
to the inhibition of TRAIL DR signaling. Taken together, these
studies demonstrate that UL141 restriction of TRAIL DR cell-
surface expression provides nonredundant protection against
TRAIL-mediated apoptosis in HCMV-infected cells.
UL141 Inhibition of TRAIL DRs Contributes to NK Cell
Inhibition
Lung epithelial cells expressing UL141 exhibited markedly
reduced cell-surface expression of TRAIL-R2 and CD155, while
intracellular levels of both molecules increased (Figures 7A and
B). Our previous studies revealed UL141 to be a potent inhibitor
of NK cell killing via downregulation of the DNAM-1-activating
ligands CD155 and CD112 (Tomasec et al., 2005) but were not
designed to measure contributions of NK-cell-mediated
apoptosis regulated by DR signaling. TRAIL is poorly expressed
Figure 4. UL141 Binds Directly to the TRAIL DR
Sensorgrams of UL141 binding to TRAIL-R1 (left) and -R2 (right). Each curve (top) represents the binding response of UL141 to both DR at a different
concentration (0.78–50 mM, left; 0.016–1 mM, right). The corresponding residual statistics representing the deviation from the fitted data to the actual response
values is shown below. The KD of 2.3 mM and 6 nM were determined for UL141ecto binding to TRAIL-R1:Fc and TRAIL-R2:Fc, respectively, immobilized on the
chip. See also Figure S3.
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blood, although, interestingly, it is present at high levels in the
small percentage of CD56hi NK (Figure S5). Consequently,
‘‘bulk’’ NK cells were first activated with interferon a (IFNa)
(Figure 7C), a physiologically relevant inducer of TRAIL during
viral infection in vivo (Sato et al., 2001; Takeda et al., 2001).
Cellular targets transduced with control adenovirus vector
were significantly more sensitive to apoptosis mediated by these
NK effectors than those expressing UL141 (Figure 7D). Anti-
DNAM-1 blocking antibody reduced NK cell killing by 65%,
and a similar reduction was seen in both control cells and those
expressing UL141. Blocking TRAIL-mediated effector functions
with soluble TRAIL-R2 also trended toward reducing NK killing
(30% reduction, p = 0.08), and analyzing results of eight sepa-
rate experiments from four individual NK cell donors revealed
that inhibiting TRAIL does significantly reduce NK-cell-mediated
killing of UL141-expressing cells (p = 0.0081, two-way ANOVA,
Figure 7E). Consistent with an important contribution of TRAIL
in NK-cell-mediated killing, the addition of soluble TRAIL-R2 in
combinationwith anti-DNAM-1 reduced killing to an even greater
extent, with more-robust reductions seen in UL141-expressing
targets when compared to control cells (11-fold versus 4.5-
fold). These results highlight a selective importance of UL141Cell Hoin promoting resistance to TRAIL. Notably, the observed sensi-
tivity of UL141-expressing targets to NK cell killing via TRAIL
and DNAM-1 is mediated by ‘‘residual’’ levels of CD155 and
TRAIL-R2 in these target cells (Figure 7A) and is very likely rele-
vant given that incomplete inhibition of their cell-surface expres-
sion is also seen in HCMV-infected cells (see Figures 1 and 2).
DISCUSSION
Here we uncover a herpesvirus protein that acts to inhibit TRAIL-
mediated apoptosis by specifically targeting cell-surface
expression of the TRAIL DRs. HCMV now joins a growing list
of DNA and RNA viruses that modulate signaling by the TRAIL/
TRAIL-R cytokine system. This study highlights the fundamental
role that signaling by TNF family cytokines plays in driving the
evolution of host attack and viral retort that is critical for the
success of persistent viral pathogens. Our data are consistent
with a model in which gpUL141 binds directly to the ectodomain
of the human TRAIL DRs in the lumen of the ER, sequestering
them as a stable complex as both proteins accumulate. Conse-
quently, transport through the Golgi apparatus and onward is
impeded, and cells are desensitized to extrinsically mediated
TRAIL killing. Notably, HCMV infection had previously beenst & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc. 329
Figure 5. UL141 Restricts Expression of TRAIL DR to the Endoplasmic Reticulum
Human fibroblasts were coinfected for 48 hr with adenovirus vectors expressing TRAIL-R2-DDeathDomain-GFP (TR2-GFP), TR2-RFP, CD155-cherry, or MICA-
GFP, as indicated. A proportion of cells were also coinfected with adenovirus vector expressing UL141 (panels F–J and P–T). Slides were counter stained with
WGA-AF350 to visualize the outline of the cells. See also Figure S4.
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UL141 Targets TRAIL Death Receptorsreported to sensitize cells to TRAIL and induce DR expression
(Sedger et al., 1999), but this can now be explained in those
studies by the use of the high-passage AD169 strain, which
encodes a defective UL36 and also lacks the entire UL/b0
genomic region (Skaletskaya et al., 2001a; Cha et al., 1996).
TRAIL expression is upregulated on the surface of HCMV-in-
fected DCs, promoting the death of virus-specific T cells that
encounter them (Raftery et al., 2001). Perhaps the commensu-
rate restriction of the TRAIL DRs by UL141 is necessary to
protect infected DCs from TRAIL-mediated fratricide and/or
suicide. TRAIL mRNA is also highly induced by HCMV in
placental fibroblasts via the action of type I IFN (Andrews et al.,
2007), suggesting a similar mechanism to thwart host immunity
may operate during congenital infection (Nigro and Adler,
2011). Consequently, HCMV may utilize the immune-suppres-
sive activities of TRAIL to its advantage, while simultaneously
inhibiting its action in infected cells via the action of UL141.
Intriguingly, and indicative of a multifaceted role for the TRAIL
DRs in CMV defense, myeloid cells from TRAIL-R2/ mice
produce increased levels of inflammatory cytokines when in-
fected with mouse CMV (MCMV), promoting increased NK cell330 Cell Host & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevieactivation and enhanced control of viral replication in the spleen,
but not the liver (Diehl et al., 2004). Although the mechanism(s)
for this inhibitory role of TRAIL DR signaling in mice is not
currently understood, it illustrates the importance of considering
cell-type- and tissue-specific roles for the TRAIL cytokine
system in regulating antiviral immune defenses.
Although CD155 and CD112 share homology, as do TRAIL-
R1 and TRAIL-R2, these proteins show no primary sequence
or predicted structural homology to each other. The crystal
structure of UL141 in complex with TRAIL-R2 reveals that its
Ig domain is utilized to interact with TRAIL-R2 (C.A.B. and
D.M.Z., unpublished data), but whether a similar mechanism
is used to bind CD155 remains an open question. Until quite
recently, interacting partners for the TNFRs were thought to
be restricted to the trimeric TNF family ligands. However,
when HVEM/TNFRSF14 was found to bind the inhibitory co-
signaling receptor BTLA, this dogma was reassessed (Sedy
et al., 2005). Interestingly, HCMV UL144 also targets this
signaling system. UL144 is a partial functional ortholog of
HVEM that binds to BTLA, but not to LIGHT, and potently
inhibits T cell proliferation (Cheung et al., 2005; Sedy´ et al.,r Inc.
Figure 6. UL141 Inhibits TRAIL-Mediated Apoptosis
(A) Human fibroblasts (HF-CAR) were infected with RAd-UL141 or RAd-CTRL
(48 hr, MOI = 3), incubated with TRAIL or TNFa as indicated, and analyzed for
caspase-3/caspase-7 activation (n = 4, error bars represent the SD).
(B) NHDF cells were either mock infected or infected with the indicated HCMV
viruses at an MOI of 2. Forty-eight hours later, 50 or 100 ng/ml purified
hTRAIL plus 5 mg/ml cycloheximide (CHX) was added for an additional 48 hr
before assessment of cell viability. In all cases, the percentage of live cells was
calculated by normalization of TRAIL+CHX-treated cells to cultures treated
with CHX only.
In (A), a Student’s t test was used for statistical analysis, and the 8 hr time point
in TNFa-treated cells has a p value of 0.048. In (B), statistical analysis was
performed with the one-way ANOVA (for both groups, ***p < 0.0001) and
displayed are Tukey’s multiple comparison post test results. Error bars in (B)
represent mean ± SEM.
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that can interact with the ectodomain of the TRAIL DRs,
providing further evidence for TNFR binding partners that
extend outside of the canonical family. It is intriguing that
UL141 binds to TRAIL-R1 with a much lower affinity than to
TRAIL-R2, as this mimics what is seen for TRAIL binding
(Truneh et al., 2000) and suggests a biological significance
that is currently underappreciated. Along these lines, TRAIL-
R2 is normally highly expressed intracellularly in uninfected
cells, with UL141 greatly enhancing these levels. The UL141-
mediated accumulation of TRAIL DR, as well as CD155, raises
the intriguing possibility that these host-cell proteins may
possess yet-to-be described roles as intracellular signalers.
UL141 is now known to be required for restricting the cell-
surface expression of at least four cellular proteins: TRAIL-R1,
TRAIL-R2, CD155, and CD112. CD155 was the first identified
target of UL141 (Tomasec et al., 2005), and the decreased sensi-
tivity of cells expressing UL141 to NK cell killing is ascribed in
part to its inhibition of NK cell activation via DNAM1. DNAM1 is
an activating receptor that is a key initial component of NK cell
activation/licensing. Killing itself can then be mediated through
cytotoxic granule release in conjunction with signaling by TNFCell Hofamily ligands that bind to cognate death receptors. In order to
assess whether UL141 restriction of TRAIL DR expression
contributes to NK inhibition, we developed a physiologically rele-
vant assay in which IFNa-activated NK cells were used as effec-
tors. Interestingly, although CD56hi NK cells only compose
a small percentage of circulating NK cells in peripheral blood
(5%), these cells express high levels of TRAIL (Figure S5).
Consequently, since many more NK cells present in human
tissues are CD56hi (Poli et al., 2009), this suggests that our
in vitro assays with NK cells isolated from blood might underre-
present the contribution of TRAIL in NK cell control of HCMV.
Also, it is important to distinguish the distinct roles played by
DNAM-1 and TRAIL in NK cell killing. DNAM-1 is involved in
the 1 ‘‘decision-making’’ process, while TRAIL participates
in executing that decision. This is highlighted by the fact that in
our assays, antibody blockade of DNAM-1 would not affect the
negative signal mediated by CD155 binding to its ‘‘paired’’ NK
cell inhibitory receptor, TIGIT (Yu et al., 2009). In total, UL141
imposes a multilayered strategy to inhibit NK cells through
dampening both their initial activation and downstream killing.
Finally, targeting of TRAIL DRs, TNFR-1, and HVEM by the
UL138-144 UL/b0 locus now defines this gene cluster as being
highly focused onmodulating signaling by the TNFR superfamily.
Additionally, UL141 and UL142 (Ashiru et al., 2009) stand out
within this cluster as having proven NK-cell-modulating func-
tions. As NK cells also express BTLA, perhaps UL144 will soon
join their ranks. Notably, UL141 and UL144 are also conserved
and immediately adjacent ORFs in the rhesus CMV genome
(Hansen et al., 2003), further emphasizing their likely importance
in CMV modulation of primate innate immunity.
EXPERIMENTAL PROCEDURES
Cells and Virus
NHDFs were obtained from Clonetics (San Diego, CA), immortalized HFFs are
described (McSharry et al., 2001), and 293T cells were from the ATCC (CRL-
11268). All cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, Pen/Strep, and L-gluta-
mine (GIBCO). Insulin and bFGF (Sigma-Aldrich) were added to NHDF media.
Cells were verified to be mycoplasma negative. AD169 was acquired from the
ATCC (VR-538, used p2-5), and Toledo was a kind gift from S. Starr (Philadel-
phia, used p12-15). Mutagenesis of FIX was performed as described (Hahn
et al., 2002), and additional primer sequences are in supplemental Table S1.
MerDUL141 generation was described (Prod’homme et al., 2010). HCMV virus
was generated by BAC transfection into fibroblasts as described (Hahn et al.,
2002; Stanton et al., 2010).
RNA Isolation and Analysis
Total RNAwas isolated from HCMV infected cells with TRIzol (Roche) followed
by an RNeasy mini kit (QIAGEN, Hilden, Germany). Complementary DNA
generation and real-time quantitative PCR analysis was as described
(Schneider et al., 2008), and primer sequences can be requested. For RACE
analysis, a 50/30 RACE kit was used (Roche), and primers were as follows:
UL141-50, 50-CCGGCGACGTGGTCTCATAA-30; UL141-30, 50-ATCGCGG
CATTTTTGGGATT-30. The amplified products were purified by agarose gel
and sequenced.
Flow Cytometry
HCMV-FIX-infected 6-well dishes of NDHFs or HFFs were detached
with diluted trypsin, washed in PBS, and resuspended in PBS + 2% fetal
calf serum. Cells were incubated with 1 antibody for 20–30 min on ice,
followed by anti-mouse IgG1 biotin (BD) and Streptavidin-APC (PharMingen)
if needed, and fixed with 1% paraformaldehyde. Anti-TRAIL-R1 andst & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevier Inc. 331
Figure 7. UL141 Blockade of Both TRAIL DR and CD155 Contributes to NK Cell Inhibition
(A) RAd control or UL141 transduced A549 cells were analyzed for expression of TRAIL-R2, CD155 and CD112 at the time of NK cell addition by flow cytometry.
(B) Western blot of RAd-transduced A549 cells.
(C) Expression of TRAIL by IFNa activated (blue) or unactivated (red) human NK cells assessed by flow cytometry.
(D) IFNa-activated NK cells were purified from human peripheral blood and added to A549 lung epithelial cells transduced with either control adenovirus vector
(Rad-Cntrl) or Rad-UL141 (effector to target [E:T] ratio of 2). Blocking aDNAM-1 antibody or blocking soluble TRAIL-R2 (10 mg/ml) was added to cultures where
indicated (+), and control mIgG or sCD30 was added as a control to the other cultures. Apoptosis of A549 cells was assessed 4 hr later. Shown are two
representative experiments of more than six performed.
(E) Summary of NK killing data from eight separate experiments and four different donors. yData aremean ± SEM from n = 1 to 3wells. *Bonferroni post test shows
significance at p < 0.05.
See also Figure S5.
Cell Host & Microbe
UL141 Targets TRAIL Death Receptorsanti-TRAIL-R2 (HS101 and HS201, Alexis), anti-MHCI (W6/32, eBioscience),
and anti CD155-PE (Biolegend) used at 5 mg/ml. Samples were acquired with
a BD LSRII or FACScalibur flow cytometer and analyzed with FlowJo soft-
ware (Tree Star). For Merlin infections, essentially the same methods were
used, with secondary detection using anti-mouseAF647 (Molecular Probes,
A-21238). Data were analyzed with Accuri/CFlowPlus. UL141 transfected332 Cell Host & Microbe 13, 324–335, March 13, 2013 ª2013 Elsevie293T cells and NHDFs were analyzed similarly, as were adenovirus-trans-
duced HFFs and purified human NK cells.
Cell Death Assays
MTT cell viability assays in HCMV-infected NHDFs (Benedict et al., 2001) and
caspase-3/caspase-7 activation assays (Skaletskaya et al., 2001a) werer Inc.
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UL141 Targets TRAIL Death Receptorsperformed essentially as described. See the Supplemental Experimental
Procedures for details.
Plasmids, Adenovirus, Proteins, and Transfections
Plasmid vectors for expressing Fc-fusion proteins are described (PCR3-Fc)
(Schneider, 2000), with details available in the Supplemental Experimental
Procedures. Adenovirus vectors expressing UL141 are described (Tomasec
et al., 2005). Generation of TRAILR2DDD.GFP, TRAILR2DDD.RFP, CD155.
RFP, and MICA.GFP recombinant adenoviruses is described (Stanton et al.,
2010), with modifications available in the Supplemental Experimental Proce-
dures. Fc-fusion proteins used in ELISA and SPR were purified by protein A
affinity from transfected 293T cell supernatants, except for TRAIL-R1:Fc
(R&D Systems). For SPR studies, cell supernatants from SF9 cells transduced
with baculovirus expressing His-tagged UL141ecto were collected after
3 days at 27.5C (MOI = 3) and were purified with Ni2+-affinity chromatography
followed by cation-exchange chromatography with MonoS (GE Healthcare)
and gel filtration (Superdex S200, GE Healthcare) by fast protein liquid
chromatography.
Dishes (6-well) of 293T were transfected with 2 mg UL141 plasmid as
described (Cheung et al., 2005). UL141 plasmid (1 mg) was cotransfected
into NHDFs with 0.5 mg provided control GFP plasmid according to manufac-
turer’s instructions (AMAXA).
Surface Plasmon Resonance Studies
SF9 cell purified UL141 was exchanged to Biacore running buffer, TRAIL DR
Fc fusion proteins and hLTbR:Fc (negative control) were immobilized on an
on an anti-human Fc capture chip, and binding was analyzed with a Biacore
3000 (GE Healthcare) essentially as described (Wang et al., 2010). See the
Supplemental Experimental Procedures for more details.
Western Blots
Cells were dissolved in NuPAGE LDS sample buffer (Invitrogen), and proteins
were resolved on NuPAGE Novex 10%Bis-Tris gels (Invitrogen), transferred to
nitrocellulose membrane (Hybond-C, GE), and treated with Antibody Extender
reagent (Pierce) per themanufacturers’ instructions. Antibodies used to probe
membranes were as follows: TRAILR2 (R&D, AF631), CD155 (5D1) (Aoki, JBC,
1994:8431), UL141 (Tomasec et al., 2005), and actin (Sigma A-2066).
Secondary antibodies were anti-mouse-HRP (BioRad 170-6516), anti-rabbit-
HRP (BioRad 170-6515), and anti-goat-HRP (SantaCruz sc-2056).
Immunofluorescence
Human fibroblasts (NPi) (Tomasec et al., 2000) were coinfected with the rele-
vant adenovirus vectors, and 48 hr after infection cells were fixed with 4%
paraformaldehyde, stained with WGA-AF350 (Molecular Probes W11263),
and imaged on Leica DMIRBEmicroscopewith Improvision Openlab software.
NK Cell Killing Assays
Purification of ‘‘bulk’’ NK cells from IFNa-activated human peripheral blood
mononuclear cell cultures has been described (Tomasec et al., 2005). See
the Supplemental Experimental Procedures for more details.
Statistical analysis
Unless otherwise noted, statistical significance was analyzed by the Student’s
t test, and data represent the mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2013.02.003.
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